Effects of Tin-Protoporphyrin IX on Blood Flow in a Rat Tumor Model

Abstract

Carbon monoxide (CO), one of the products of heme oxygenase (HO) catalyzed heme degradation, is a vasodilator. The aim of the present study was to clarify the role of HO in blood flow maintenance in tumors. Male BD9 rats bearing subcutaneous transplants of the P22 carcinosarcoma tumor were treated intraperitoneally (ip) with either tin-protoporphyrin IX (SnPP; 45 μmol/kg), a selective inhibitor of HO or copper-protoporphyrin IX (CuPP; 45 μmol/kg), used as a negative control. The extent of HO activity inhibition was measured using a spectrophotometric assay of bilirubin production and blood flow rates to the tumor and a range of normal tissues were assessed using the uptake of the radiolabelled tracer, iodo-antipyrine (¹²⁵I-IAP). The animals were cannulated under fentanyl citrate/fluanisone (Hypnorm)/midazolam anesthesia. In the P22 tumor, SnPP, but not CuPP, caused a complete inhibition of HO activity 15 min post-treatment. Administration of SnPP 15 min before blood flow measurements reduced tumor blood flow by 17%, with no effects in any of the normal tissues studied. However, CuPP induced a greater reduction in tumor blood flow than SnPP (45% decrease). Furthermore, CuPP caused a reduction in blood flow to the skin and small intestine but a significant increase to skeletal muscle. The current findings conclusively establish only a minor role played by the HO/CO system in the maintenance of blood flow in this tumor system, despite relatively high levels of HO-1 protein and HO activity. The results also highlight the potential usefulness of CuPP as a tumor blood flow modifier.

Get full access to this article

View all access options for this article.

References

Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82 : 4–6, 1990.

Chaplin DJ, Hill SA, Bell KM, Tozer GM. Modification of tumour blood flow: Current status and future directions. Semin Radiat Oncol 8 : 151–163, 1998.

Tozer GM, Everett SA. Nitric oxide in tumour biology and cancer therapy. Part 1: Physiological aspects. Clin Oncol 9 : 282–293, 1997.

Tozer GM, Prise VE, Chaplin DJ. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 57 : 948–955, 1997.

Orucevic A, Lala PK. N^G-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Br J Cancer 73 : 189–196, 1996.

Wang R, Wang Z, Wu L. Carbon monoxide-induced vasorelaxation and the underlying mechanisms. Br J Pharmacol 121 : 927–934, 1997.

Lin H, McGrath JJ. Vasodilating effects of carbon monoxide. Drug Chem Toxicol 11 : 371–385, 1988.

Vedernikov YP, Graser T, Vanin AF. Similar endothelium-independent arterial relaxation by carbon monoxide and nitric oxide. Biomed Biochim Acta 48 : 601–603, 1989.

Graser T, Vedernikov YP. Li DS. Study on the mechanism of carbon monoxide induced endothelium-independent relaxation in porcine coronary artery and vein. Biomed Biochim Acta 49 : 293–296, 1990.

10.

Zhang F, Kaide JI, Rodriguez-Mulero F, Abraham NG, Nasjletti A. Vasoregulatory function of the heme-heme oxygenase-carbon monoxide system. Am J Hypertens 14 : 62S–67S, 2001.

11.

Suematsu M, Kashiwagi S, Sano T, Goda N, Shinoda Y, Ishimura Y. Carbon monoxide as an endogenous modulator of hepatic vascular perfusion. Biochem Biophys Res Commun 205 : 1333–1337, 1994.

12.

Suematsu M, Goda N, Tsuyoshi S, Kashiwagi S, Egawa T, Shinoda Y. Carbon monoxide: An endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 96 : 2431–2437, 1995.

13.

Hara E, Takahashi K, Tominaga T, Kumabe T, Kayama T, Suzuki H, Fujita H, Toshimoto T, Shirato K, Shibahara S. Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumours. Biochem Biophys Res Commun 224 : 153–158, 1996.

14.

Maines MD, Abrahamsson PA. Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumour tissue distribution. Urology 47 : 727–733, 1996.

15.

Nishie A, Ono M, Shono T, Fukushi J, Otsubo M, Onoue H, Ito Y, Inamura T, Ikezaki K, Fukui M, Iwaki T, Kuwano M. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 5 : 1107–1113, 1999.

16.

Torisu-Itakura H, Furue M, Kuwano M, Ono M. Co-expression of thymidine phosphorylase and heme-oxygenase-1 in macrophages in human malignant vertical growth melanomas. Jpn J Cancer Res 91 : 906–910, 2000.

17.

Yokoyama S, Mita S, Okabe A, Abe M, Ogawa M. Prediction of radiosensitivity in human oesophageal squamous cell carcinomas with heme oxygenase-1: A clinicopathological and immunohistochemical study. Oncol Rep 8 : 355–358, 2001.

18.

Tozer GM, Prise VE, Motterlini R, Poole BA, Wilson J, Chaplin DJ. The comparative effects of the NOS inhibitor, N^ω-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow. Int J Radiat Oncol Biol Phys 42 : 849–853, 1998.

19.

Drummond GS, Kappas A. Prevention of neonatal hyperbilirubinemia by tin protoporphyrin IX, a potent competitive inhibitor of heme oxidation. Proc Natl Acad Sci USA 78 : 6466–6470, 1981.

20.

Zakhary R, Gaine SP, Dinerman JL, Ruat M, Flavahan NA, Snyder SH. Heme oxygenase-2: Endothelial and neuronal localisation and role in endothelium-dependent relaxation. Proc Natl Acad Sci USA 93 : 795–798, 1996.

21.

Tozer GM, Shaffi KM. Modification of tumour blood flow using the hypertensive agent, angiotensin II. Br J Cancer 67 : 981–988, 1993.

22.

Motterlini R, Foresti R, Intaglietta M, Winslow RM. NO-mediated activation of hemeoxygenase: endogenous cytoprotection against oxidative stress to the endothelium. Am J Physiol 270 : H107–H114, 1996.

23.

Kety SS. Theory of blood tissue exchange and its application to measurements of blood flow. Methods Med Res 8 : 223–236, 1960.

24.

Kappas A, Drummond GS. Control of heme metabolism with synthetic metalloporphyrins. J Clin Invest 77 : 335–339, 1986.

25.

Anderson KE, Simionatto CS, Drummond GS, Kappas A. Tissue distribution and disposition of tin-protoporphyrin, a potent competitive inhibitor of heme oxygenase. J Pharmacol Exp Ther 228 : 327–333, 1984.

26.

Hintz SR, Kim CB, Vreman HJ, Stevenson DK. Lack of inhibition of intestinal heme oxygenase by antibiotics and tin-protoporphyrin. Pediatr Res 23 : 50–53, 1988.

27.

Grundemar L, Ny L. Pitfalls using metalloporphyrins in carbon monoxide research. Trends Pharmacol Sci 18 : 193–195, 1997.

28.

Ny L, Andersson KE, Grundemar L. Inhibition by zinc protoporphyrin-IX of receptor-mediated relaxation of the rat aorta in a manner distinct from inhibition of haem oxygenase. Br J Pharmacol 115 : 186–190, 1995.

29.

Maines MD, Trekshel GM. Differential regulation of heme oxygenase isozymes by Sn- and Zn-protoporphyrins: Possible relevance to suppression of hyperbilirubinemia. Biochim Biophys Acta 1131 : 166–174, 1992.

30.

Khelifi AF, Prise VE, Foresti R, Clark JE, Kanthou C, Motterlini R, Tozer GM. Heme oxygenase and the novel tumour-specific anti-vascular compound combretastatin A4-phosphate. In: Abraham NG, Alam J, Nath KA, Eds. Heme Oxygenase in Biology and Medicine. New York: Kluwer Academic/Plenum Publishers, p303, 2002.

31.

Deramaudt BM, Braunstein S, Remy P, Abraham NG. Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis. J Cell Biochem 68 : 121–127, 1998.

32.

Doi K, Akaike T, Fujii S, Tanaka S, Ikebe N, Beppu T, Shibahara S, Ogawa M, Maeda H. Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br J Cancer 80 : 1945–1954, 1999.